Back

Half-Dose Anticoagulation versus Standard Antiplatelet Therapy for Preventing Silent Cerebral Embolism After Left Atrial Appendage Occlusion: The HALO-SCE Randomized Trial

31 August 2026 (13:00 - 13:15)
Organised by: Logo
Congress Presentation Part of: Advances in stroke prevention: anticoagulation, antiplatelet therapy and left atrial appendage closure Oral Anticoagulation ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Ju Weizhu

The First Affiliated Hospital of Nanjing Medical University, Nanjing (China)

3 More presentations in this session

Presentation thumbnail
Dual antiplatelet therapy (DAPT) during the first 90 days post-randomisation in OCEANIC-STROKE: participant characteristics and interaction with asundexian
Professor M. Sharma (Hamilton, CA)
Slides Video
Presentation thumbnail
Sex-Specific Outcomes of Left Atrial Appendage Closure Versus Medical Therapy: The CLOSURE-AF-DZHK-16 Trial
Professor I. Eitel (Luebeck, DE)
Slides Video
Presentation thumbnail
Left Atrial Appendage Closure as an Alternative to NOAC for Stroke Prevention in Patients with Atrial Fibrillation at Low Bleeding Risk: A Patient-Level Meta-Analysis
Doctor M. Coylewright (Duluth, US)
Slides Video

Access the full session

Session thumbnail
Advances in stroke prevention: anticoagulation, antiplatelet therapy and left atrial appendage closure
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Reduced-dose direct oral anticoagulation vs antiplatelet strategies after left atrial appendage occlusion in atrial fibrillation. a triple target trial emulation from a federated research network
29 August 2026
thumbnail
Congress Presentation
Insights into the latest clinical data
12 April 2026
thumbnail
Congress Presentation
An observational analysis of device-related thrombus in patients with atrial fibrillation across different generations of Watchman devices
31 August 2025
thumbnail
Congress Session
Late-breaking science on valve disease and hypertrophic cardiomyopathy
28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources